Redmile Group, LLC Expands Stake in Atara Biotherapeutics Inc
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Atara Biotherapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Sector Update: Health Care Stocks Softer Late Afternoon
Top Midday Gainers
Atara Biotherapeutics (ATRA) Stock Is Up 20%: What's Going On?
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Wednesday as Nvidia Slump Continues
Why GitLab Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
Atara Biotherapeutics Announces Board Appointment and Capital Raise
Express News | Atara Biotherapeutics Inc - Well Positioned to Execute on Tab-Cel U.S. Bla Approval and Advancement of ATA3219
Express News | Atara Biotherapeutics Inc - Further Strengthens Balance Sheet With Cash Runway Into 2027 Enabling Key Pipeline Readouts
Express News | Atara Biotherapeutics Announces $36 Million Registered Direct Offering
HC Wainwright & Co. Reiterates Neutral on Atara Biotherapeutics
H.C. Wainwright Maintains Atara Biotherapeutics(ATRA.US) With Hold Rating
H.C. Wainwright analyst Robert Burns maintains $Atara Biotherapeutics(ATRA.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 27.8% and a total average return of -19
Atara Biotherapeutics: Hold Rating Maintained Amid Financial Shortfalls and Regulatory Uncertainties
Atara Biotherapeutics (ATRA) Gets a Hold From Stifel Nicolaus
Mizuho Securities Upgrades Atara Biotherapeutics(ATRA.US) to Buy Rating, Cuts Target Price to $18
Mizuho Securities analyst Salim Syed upgrades $Atara Biotherapeutics(ATRA.US)$ to a buy rating, and adjusts the target price from $25 to $18.According to TipRanks data, the analyst has a success
Express News | Atara Biotherapeutics Inc : Mizuho Raises to Outperform From Neutral; Cuts Target Price to $18 From $25
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Just Reported Earnings, And Analysts Cut Their Target Price
Atara Biotherapeutics Second Quarter 2024 Earnings: Misses Expectations